MajesTEC-1: Efficacy and Safety of Teclistamab
Experts on multiple myeloma review the study design and results from MajesTEC-1, focusing on the efficacy and safety findings, and provide insights on adverse event management practices.
Video Player is loading.
EP: 1.The Current Treatment Landscape for Relapsed/Refractory Multiple Myeloma
Now Viewing
EP: 2.MajesTEC-1: Efficacy and Safety of Teclistamab
EP: 3.Teclistamab Dosing and Adverse Event Prophylaxis Practices
EP: 4.Clinical Implications of MajesTEC-1
EP: 5.Long-Term Data Affirm Enduring Responses With Teclistamab in R/R Multiple Myeloma
Video content above is prompted by the following question:
- What were the efficacy and safety findings from the long-term follow-up from MajesTEC-1?
Recent Videos
CAR T vs Bispecifics: Expanding CAR T Reach in B-Cell Malignancies
Real-World Use, Outpatient Dosing and Transitions of Care in Academic and Community Settings
A Review of Outpatient Step-Up Dosing for Talquetamab in R/R MM
PERSEUS Trial: MRD Negativity
PERSEUS Trial: Design/Baseline Characteristics
Treatment Overview of Transplant-Eligible Newly Diagnosed Multiple Myeloma
Understanding ICANS Management With CAR T: Low-Grade Events With High Resolution Rates
CEPHEUS Trial: Adverse Events
CRS Management Insights With Liso-Cel: Comprehensive Analysis From Real-World Data in 1579 Patients and Implications for Safe Clinical Practice
Talquetamab in R/R MM: Managing GPRC5D-direced AEs, Prophylaxis, and New Safety Signals
Related Content
